Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

From biophysical chemistry to cell biology: Deciphering the role of lipids in the toxicity and spreading of protein aggregation

Project description

Amyloid protein-lipid aggregates roles in severe diseases

Amyloid proteins (amylin, amyloid beta, and α-synuclein) have been linked to type 2 diabetes, Alzheimer’s disease, and Parkinson’s disease, respectively. This highlights the role of lipids in membrane damage and supports the lipid-chaperone hypothesis. With the support of the Marie Skłodowska-Curie Actions programme, the LIPAGG project will investigate amyloid protein-lipid aggregates and their roles in diseases like Alzheimer’s, Parkinson’s, and type 2 diabetes. Focusing on amylin, amyloid beta, and α-synuclein, it will explore cellular toxicity, aggregation mechanisms, and interactions with lipid membranes. The project will train doctoral candidates to develop strategies to inhibit harmful aggregate formation. Overall, it aims to enhance our understanding and potential treatments for these diseases.

Objective

The LIPAGG project seeks to unravel the structural complexities of amyloid protein-lipid aggregates and investigate their role in pathological aggregation, cellular toxicity, and intercellular spread. Focusing on key human amyloid proteins—amylin (IAPP), amyloid beta (Aβ), and α-synuclein (αS)—linked to type 2 diabetes (T2D), Alzheimer's disease (AD), and Parkinson’s disease (PD), respectively, the project builds on recent discoveries made by the consortium. These findings highlight the critical role of free lipids in membrane damage through the formation of stable lipid-amyloidogenic protein complexes, leading to the lipid-chaperone hypothesis.

The project will explore unresolved mechanisms linking amyloid aggregation to cellular damage, focusing on three key aspects: 1) the toxicity of prefibrillar amyloid oligomers, 2) the interaction of amyloid proteins with lipid membranes, and 3) the pathological spread of amyloid aggregates in the brain. Guided by the lipid-chaperone hypothesis, the consortium will train fifteen Doctoral Candidates (DCs), emphasizing the pivotal role of lipids in amyloid-related diseases. The training program will include cutting-edge methods in biophysics, peptide chemistry, molecular and structural biology, and cell biology.

The scientific objectives of LIPAGG include characterizing amyloid-lipid complexes, understanding their impact on aggregation and membrane integrity, assessing their effects on cellular viability and intercellular spread, and developing chemical tools to block the formation of these complexes, offering potential therapeutic strategies. The results will have significant societal impact, enhancing our understanding of AD, PD, and T2D, including potential improvements in diagnostic and therapeutic approaches. With support of a consortium of 23 partners from 8 countries, DCs will have access to state-of-the-art instrumentation, including 1.2 GHz NMR spectrometers, single-particle cryo-EM facilities, and supercomputers.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-TMA-MSCA-DN - HORIZON TMA MSCA Doctoral Networks

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-MSCA-2024-DN-01

See all projects funded under this call

Coordinator

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS
Net EU contribution
€ 314 669,16
Address
RUE MICHEL ANGE 3
75794 Paris
France
Region
Ile-de-France Ile-de-France Paris
Activity type
Research Organisations
Links
Total cost
No data

Participants (7)

Partners (15)